| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 12 | 2019 | 761 | 1.070 |
Why?
|
| Brain Neoplasms | 10 | 2020 | 638 | 0.980 |
Why?
|
| Endothelium, Vascular | 8 | 2018 | 156 | 0.970 |
Why?
|
| Angiopoietin-1 | 4 | 2012 | 5 | 0.590 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 72 | 0.550 |
Why?
|
| Gap Junctions | 1 | 2015 | 2 | 0.520 |
Why?
|
| Connexin 43 | 1 | 2015 | 4 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 82 | 0.480 |
Why?
|
| Endothelial Cells | 1 | 2015 | 189 | 0.460 |
Why?
|
| Brain Injuries | 3 | 2018 | 93 | 0.390 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 725 | 0.370 |
Why?
|
| Animals | 20 | 2020 | 7466 | 0.360 |
Why?
|
| Receptor, TIE-2 | 3 | 2005 | 5 | 0.330 |
Why?
|
| Cell Proliferation | 8 | 2020 | 599 | 0.330 |
Why?
|
| Mice | 11 | 2020 | 2475 | 0.320 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 110 | 0.310 |
Why?
|
| Radiosurgery | 3 | 2017 | 356 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 211 | 0.290 |
Why?
|
| Radiation Injuries | 3 | 2017 | 72 | 0.280 |
Why?
|
| Gene Expression | 2 | 2018 | 335 | 0.280 |
Why?
|
| Angiopoietins | 1 | 2005 | 2 | 0.250 |
Why?
|
| Mesoderm | 1 | 2004 | 14 | 0.250 |
Why?
|
| Mesothelioma | 2 | 2001 | 39 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 111 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2018 | 63 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 99 | 0.200 |
Why?
|
| Humans | 23 | 2020 | 32024 | 0.200 |
Why?
|
| Receptor, erbB-2 | 3 | 2019 | 65 | 0.200 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2001 | 14 | 0.190 |
Why?
|
| Mice, Nude | 6 | 2020 | 290 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 57 | 0.190 |
Why?
|
| Sulfones | 1 | 2020 | 21 | 0.180 |
Why?
|
| Microglia | 2 | 2018 | 57 | 0.180 |
Why?
|
| Indans | 1 | 2020 | 31 | 0.180 |
Why?
|
| Fibronectins | 2 | 2018 | 36 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 46 | 0.180 |
Why?
|
| Angiotensin I | 2 | 2013 | 240 | 0.180 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2013 | 398 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 45 | 0.160 |
Why?
|
| Glioblastoma | 1 | 2020 | 156 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 409 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2018 | 34 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 33 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2019 | 180 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 101 | 0.150 |
Why?
|
| Astrocytes | 2 | 2019 | 58 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 61 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 92 | 0.150 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 607 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2016 | 687 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 181 | 0.150 |
Why?
|
| Calcium | 1 | 2019 | 307 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2015 | 508 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 49 | 0.140 |
Why?
|
| Brain | 4 | 2018 | 950 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 51 | 0.140 |
Why?
|
| Neoplasms | 1 | 2003 | 692 | 0.140 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 245 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2018 | 180 | 0.130 |
Why?
|
| Epilepsy | 1 | 2017 | 82 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 261 | 0.130 |
Why?
|
| Hippocampus | 2 | 2014 | 171 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 194 | 0.130 |
Why?
|
| Culture Media, Conditioned | 1 | 2015 | 51 | 0.130 |
Why?
|
| Cell Communication | 1 | 2015 | 32 | 0.130 |
Why?
|
| Female | 13 | 2019 | 19953 | 0.120 |
Why?
|
| Cesium Radioisotopes | 1 | 2014 | 5 | 0.120 |
Why?
|
| Cosmic Radiation | 1 | 2014 | 14 | 0.120 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 5 | 0.110 |
Why?
|
| Models, Biological | 3 | 2019 | 391 | 0.110 |
Why?
|
| Oxygen | 1 | 2014 | 142 | 0.110 |
Why?
|
| PPAR alpha | 1 | 2014 | 29 | 0.110 |
Why?
|
| Rats | 5 | 2014 | 1596 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2013 | 137 | 0.110 |
Why?
|
| Cognition | 2 | 2014 | 553 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.110 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 532 | 0.100 |
Why?
|
| Cell Movement | 2 | 2020 | 170 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2018 | 142 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2018 | 189 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2010 | 230 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2014 | 384 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 494 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 8 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2010 | 292 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 30 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 885 | 0.090 |
Why?
|
| Male | 9 | 2019 | 19195 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 170 | 0.080 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2006 | 2 | 0.080 |
Why?
|
| Time Factors | 4 | 2013 | 2152 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 351 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2280 | 0.070 |
Why?
|
| Inflammation | 3 | 2016 | 540 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2018 | 285 | 0.070 |
Why?
|
| Malvaceae | 1 | 2005 | 1 | 0.060 |
Why?
|
| Proanthocyanidins | 1 | 2005 | 1 | 0.060 |
Why?
|
| Biflavonoids | 1 | 2005 | 1 | 0.060 |
Why?
|
| Catechin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Placentation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2005 | 7 | 0.060 |
Why?
|
| Arteriovenous Malformations | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 24 | 0.060 |
Why?
|
| Hematopoiesis | 1 | 2005 | 33 | 0.060 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2004 | 1 | 0.060 |
Why?
|
| Laminin | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 33 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2004 | 24 | 0.060 |
Why?
|
| Actins | 1 | 2004 | 52 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 32 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 45 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 40 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2005 | 61 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 95 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 70 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2005 | 65 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1505 | 0.060 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 133 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 261 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2004 | 89 | 0.060 |
Why?
|
| Middle Aged | 5 | 2019 | 11868 | 0.060 |
Why?
|
| Wound Healing | 1 | 2005 | 185 | 0.060 |
Why?
|
| Salvage Therapy | 2 | 2016 | 134 | 0.060 |
Why?
|
| Collagen | 1 | 2004 | 225 | 0.060 |
Why?
|
| Apoptosis | 2 | 2002 | 354 | 0.050 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2013 | 29 | 0.050 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2001 | 1 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 766 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 102 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pregnancy | 1 | 2005 | 994 | 0.050 |
Why?
|
| Autocrine Communication | 1 | 2001 | 7 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2001 | 9 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 85 | 0.050 |
Why?
|
| Aged | 4 | 2019 | 10340 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 168 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 31 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 35 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2000 | 61 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 114 | 0.050 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 73 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 103 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 61 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 323 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 95 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 101 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2013 | 833 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 23 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 120 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 108 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 311 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1017 | 0.030 |
Why?
|
| Adult | 3 | 2018 | 9366 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2014 | 31 | 0.030 |
Why?
|
| Respiration | 1 | 2014 | 27 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2014 | 6 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 26 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 16 | 0.030 |
Why?
|
| Space Flight | 1 | 2014 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 78 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2014 | 25 | 0.030 |
Why?
|
| Ramipril | 1 | 2013 | 4 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 31 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 300 | 0.030 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2013 | 24 | 0.030 |
Why?
|
| Tetrazoles | 1 | 2013 | 61 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 91 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 62 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2014 | 73 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 507 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2283 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 63 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 163 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2014 | 250 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 81 | 0.030 |
Why?
|
| Body Weight | 1 | 2014 | 310 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 155 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 325 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 456 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 435 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 409 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 43 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 52 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3523 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 91 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 4000 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 64 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 118 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3317 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 2005 | 2 | 0.020 |
Why?
|
| Serine | 1 | 2005 | 10 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 2615 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2005 | 51 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2005 | 81 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 79 | 0.020 |
Why?
|
| Breast | 1 | 2005 | 61 | 0.020 |
Why?
|
| Antioxidants | 1 | 2005 | 114 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 142 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 186 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Thymidine | 1 | 2001 | 6 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 18 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 11 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 9 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2001 | 31 | 0.010 |
Why?
|
| Caspases | 1 | 2001 | 38 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 47 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 89 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 122 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 37 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 103 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 80 | 0.010 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2001 | 50 | 0.010 |
Why?
|
| Vasodilation | 1 | 2002 | 93 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 356 | 0.010 |
Why?
|
| Amidines | 1 | 2000 | 2 | 0.010 |
Why?
|
| Benzylamines | 1 | 2000 | 5 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 2000 | 10 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 14 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2000 | 15 | 0.010 |
Why?
|
| Asbestos | 1 | 2000 | 8 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 47 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2000 | 40 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2000 | 67 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 165 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 257 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 629 | 0.010 |
Why?
|
| Lung | 1 | 2000 | 255 | 0.010 |
Why?
|